Cancer News and Research

Latest Cancer News and Research

NASDAQ Stock Market issues notification letter to GenVec

On September 15, 2009, GenVec, Inc. (Nasdaq: GNVC) received a notice from The NASDAQ Stock Market stating that the minimum bid price of the Company's common stock was below $1.00 per share for 30 consecutive business days and that the Company was therefore not in compliance with Marketplace Rule 5450(a)(5).

17 Sep 2009

BioMedReports.Com's news report on CEL-SCI's key developments

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special news report on key developments at CEL-SCI Corporation.

17 Sep 2009

Mayo Clinic Health Letter discusses kidney stone treatment options

Ordinary, loud snoring doesn't seem to be harmful, according to the September issue of Mayo Clinic Health Letter. But snorers still may want to seek treatment to stop snoring, reduce embarrassment and improve sleep for themselves and their bed partner.

17 Sep 2009

Pharmabcine raises funds to develop therapeutic antibodies in the area of cancer and inflammation

PharmAbcine, a specialized biotech company focused on the development of fully-human monoclonal antibodies for the treatment of cancer and inflammatory diseases, announced that is has received $6 million USD in a Series A financing. OrbiMed's Caduceus Asia Partners and Novartis Korea Venture Fund co-led the round, with additional participation from an international syndicate including Green Cross, Tong Yang and Saehan Venture Fund.

17 Sep 2009

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

Bayer HealthCare today announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar(R) (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin(TM) - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany.

17 Sep 2009

Mayo Clinic Women's HealthSource discusses myths and facts about ovarian cancer

But not all the news about ovarian cancer is grim. Incidence is declining. Doctors are learning more about early symptoms and more effective treatments. The September issue of Mayo Clinic Women's HealthSource looks at myths and facts about ovarian cancer.

17 Sep 2009

Underlying malignancies can cause rebleeding after negative angiography

Acute non-variceal gastrointestinal bleeding accounts for approximately 20% of emergency room visits and 5% of admissions. Although endoscopy has been used as a first-line treatment option in patients with gastrointestinal bleeding, angiographic intervention can be used as a safe diagnostic and treatment method in patients with gastrointestinal bleeding that is refractory to endoscopic treatment.

17 Sep 2009

Mechanism of action of the anti-cancer drug GMX1778 identified

Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced a new study has been published identifying the mechanism of action of the anti-cancer drug GMX1778. Co-authored by scientists at Gemin X Pharmaceuticals and Metabolon, the paper “The Small Molecule GMX1778 is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in NAPRT1-Deficient Tumors” appears online ahead of print in Molecular and Cellular Biology.

17 Sep 2009

Amgen granted approval to use ImmunoGen’s maytansinoid TAP technology

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, today announced that Amgen Inc. has licensed the exclusive right to use the Company’s maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target found on solid tumors.

17 Sep 2009

Liver transplantation performed in a six-month old infant

Ila and her worried parents were referred to Lucile Packard Children's Hospital at Stanford, home of the busiest pediatric liver transplant team in the nation. The hospital's team performed more liver transplants in 2008 – the most recent reporting period – than any other U.S. children's hospital, according to the United Network for Organ Sharing. They also did the largest number of surgeries in infants like Ila, who were younger than one year when they received a transplant.

17 Sep 2009

Seegene awarded patent in the U.S. and Europe for Annealing Control Primer

Seegene, Inc., a leader in multi-pathogen diagnostic testing, today announced that it has been awarded patent in the U.S. and Europe for Annealing Control Primer (ACP), a new technology for amplifying a specific region of a gene with much higher specificity and reproducibility than conventional approaches.

17 Sep 2009

Findings may lead to drugs that destroy TB in dormant stage of lifecycle

Attempts to eradicate tuberculosis (TB) are stymied by the fact that the disease-causing bacteria have a sophisticated mechanism for surviving dormant in infected cells. Now, a team of scientists led by researchers from Weill Cornell Medical College has identified compounds that inhibit that mechanism -- without damaging human cells.

17 Sep 2009

Guide reveals that non-smokers require different treatment for lung cancer

A committee of scientists led by Johns Hopkins investigators has published a new guide to the biology, diagnosis and treatment of lung cancer in never-smokers, fortifying measures for what physicians have long known is a very different disease than in smokers.

17 Sep 2009

Learning curve method checks the proficiency level in laparoscopic splenectomy procedures

A research team, led by Dr. Tarik Z. Nursal from the University of Baskent, has investigated the proficiency level reached in laparoscopic splenectomy procedures using the learning curve method. Their study will be published on August 28, 2009 in the World Journal of Gastroenterology.

17 Sep 2009

Quest PharmaTech reports second quarter fiscal 2009 results

Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer and dermatological conditions, today announced fiscal second quarter results for the period ended July 31, 2009.

17 Sep 2009

FDA provides PMA approval for Spectrascience's WavSTAT technology enhancements

SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, today announced that its application for premarket approval (PMA) relating to key enhancements of its WavSTAT platform technology has been approved by the Food and Drug Administration. The Company can now begin commercial distribution of the enhanced WavSTAT technology.

17 Sep 2009

Melbourne's national approach for managing chronic pain

An unprecedented gathering of some of Australia's leading authorities in pain medicine, together with consumer groups representing chronic pain sufferers, will meet in Melbourne today to work towards a national, coordinated approach to managing chronic pain.

17 Sep 2009

Expo East 2009 conference to focus on integrative cancer care model

People diagnosed with cancer have a number of treatment options to choose from and increasingly, alternative and complementary therapies such as yoga, meditation, healing touch, music therapy, and nutritional supplementation are among them.

17 Sep 2009

ColoMarker assay achieves 100 percent detection rate for colon cancers

Marking a major milestone in the early detection and management of colon cancer, EDP Biotech Corporation (EDP), a developer of immunodiagnostic tests for humans and animals, announced today that its ColoMarker assay achieved 100 percent detection rate for colon cancers presented at stages I through III in pre-clinical trials.

17 Sep 2009

Multi-detector row computed tomography predicts malignancy of IPMNs

A clinical research article to be published on August 28, 2009 in the World Journal of Gastroenterology addresses the role of multi-detector row computed tomography (MDCT) in predicting malignancy of IPMNs preoperatively. The research team led by Prof. Wang DB from Ruijin Hospital of Shanghai Jiao Tong University School of Medicine recruited a total of 20 patients with pathologically-confirmed IPMNs in their study. Axial MDCT images combined with CT angiography (CTA) and multiplanar volume or curved reformations (MPVR or CR) were preoperatively acquired.

17 Sep 2009